Home > Insider Trading > Filing (0001735276-21-000020)

Filing Details

Accession Number:: 0001735276-21-000020
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-26 16:03:20
Reporting Period:: 2021-02-24

Accepted Time:: 2021-02-26 16:03:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1180432	John Maraganore	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-25	33,979	$7.10	240,015	No	4	M	Direct
Common Stock	Disposition	2021-02-25	1,001	$143.88	239,014	No	4	S	Direct
Common Stock	Disposition	2021-02-25	6,129	$145.15	232,885	No	4	S	Direct
Common Stock	Disposition	2021-02-25	9,376	$146.13	223,509	No	4	S	Direct
Common Stock	Disposition	2021-02-25	6,097	$146.98	217,412	No	4	S	Direct
Common Stock	Disposition	2021-02-25	4,375	$148.00	213,037	No	4	S	Direct
Common Stock	Disposition	2021-02-25	1,364	$148.96	211,673	No	4	S	Direct
Common Stock	Disposition	2021-02-25	2,054	$150.22	209,619	No	4	S	Direct
Common Stock	Disposition	2021-02-25	1,415	$151.31	208,204	No	4	S	Direct
Common Stock	Disposition	2021-02-25	1,138	$152.46	207,066	No	4	S	Direct
Common Stock	Disposition	2021-02-25	431	$153.33	206,635	No	4	S	Direct
Common Stock	Disposition	2021-02-25	599	$154.59	206,036	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2021-02-24	79,998	$0.00	79,998	$151.59
Common Stock	Stock Option (right to buy)	Disposition	2021-02-25	33,979	$0.00	33,979	$7.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
79,998		2031-02-23	No	4	A	Direct
101,936		2021-11-30	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,133	Indirect	by Managed Account

Footnotes

All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021.
Sale prices ranged from $143.50 to $144.43.
Sale prices ranged from $144.54 to $145.54.
Sale prices ranged from $145.55 to $146.55.
Sale prices ranged from $146.59 to $147.59.
Sale prices ranged from $147.60 to $148.59.
Sale prices ranged from $148.66 to $149.65.
Sale prices ranged from $149.73 to $150.62.
Sale prices ranged from $150.88 to $151.68.
Sale prices ranged from $151.92 to $152.76.
Sale prices ranged from $153.05 to $153.90.
Sale prices ranged from $154.37 to $154.68.
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2020. The reporting person also received 42,879 performance stock units that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest.
The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.